Helix BioPharma Corp.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Thomas J. Mehrling
- Full Time Employees
- 8
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 1055 West Georgia Street Toronto BC Canada V6E 3P3
- IPO Date
- Jun 3, 1996
- Website
- helixbiopharma.com
- Similar Companies
- Business
- Helix BioPharma Corp Helix BioPharma Corp. is a clinical-stage biopharmaceutical company focused on developing innovative therapies in immuno-oncology for the prevention and treatment of hard-to-treat cancers, including solid tumors and hematological malignancies; its lead product candidate, L-DOS47 (Tumor Defense Breaker), is a first-in-class antibody-enzyme conjugate targeting CEACAM6-overexpressing tumors such as non-small cell lung cancer, designed to neutralize the acidic tumor microenvironment and enhance immune checkpoint inhibitors like pembrolizumab, with Phase Ib trials completed; additional pipeline assets include LEUMUNA, an oral immune checkpoint modulator for post-allogeneic stem cell transplant leukemia relapse with US FDA Orphan Drug Designation and patent protection to 2041, and GEMCEDA, an oral prodrug of gemcitabine offering near-intravenous bioavailability for advanced cancers with patent coverage to 2043; the company also advances three CEACAM6-specific antibody-drug conjugates in discovery. Founded in 1995 and headquartered at Bay Adelaide Centre – North Tower, 40 Temperance Street, Suite 2, Toronto, Ontario, Canada, Helix BioPharma Corp. operates primarily in Canada with international clinical development activities. Recent developments include entering an asset purchase agreement in November 2024 with Laevoroc Immunology AG to acquire oral immune checkpoint assets, revising acquisition agreements with Laevoroc Immunology AG and Laevoroc Chemotherapy AG in December 2024 to finalize share consideration ahead of financing, completing the acquisition of certain oncology assets from Laevoroc entities in May 2025, and signing a capital-raising agreement in May 2025 with Kerentech Consulting Ltd. to support a USD 13 million bridge financing round aimed at advancing L-DOS47 and other priorities through 2025 and beyond.
Company News
Helix BioPharma Corp. Appoints Markus Loeffler, MD, MBA, as Chief Medical Officer to Support Next Phase of Clinical Development
Helix Biopharma Corp. Announces Board Composition Changes
Helix BioPharma Corp. Strengthens Executive Leadership to Support U.S. Listing Strategy and Next Phase of Clinical Development
Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026
Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures
Helix BioPharma Corp. Announces Grant and Cancellation of Stock Options
Helix Biopharma Corp. Announces Strategic Board and Governance Appointments to Support Financing and Nasdaq Uplisting Strategy
Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026
Helix BioPharma Corp. Announces Presentation at 16th Annual World ADC London
Helix Biopharma Corp. Extends LEUMUNA Option with metaShape Pharma for Adipose Tissue-Related and Metabolic Diseases
Helix BioPharma Corp. Announces Voting Results from its Annual General and Special Meeting
Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three-Month Period Ended October 31, 2025
Helix BioPharma Corp. Announces Fiscal 2025 Year-End Results
Helix BioPharma Responds to Market Activity
Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025
Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025
Helix BioPharma Concludes Review, Will Not Proceed with Proposed Equity Draw-Down Subscription Facility with GEM
Helix Biopharma Corp. Announces Closing of Private Placement, in Preparation for Institutional Investment and NASDAQ Uplisting
Helix Biopharma Corp. Announces Publication in Frontiers in Oncology on the Effects of L-DOS47 as Monotherapy in NSCLC
Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Nine Month Period Ended April 30, 2025